LAVA Therapeutics Cash Flow Statement

Financials in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Jan 1, 2020
Net Income	-28.59	-41.97	-31.91	-42.36	-15.93	-9.69
Depreciation & Amortization	1.21	1.28	0.78	0.56	0.46	0.26
Loss (Gain) From Sale of Investments	-2.1	-1.9	-0.13	0.45	-	-
Stock-Based Compensation	4.5	5.04	4.11	3.91	0.56	0.19
Other Operating Activities	-0.19	1.41	-2.92	-2.04	0.87	-
Change in Accounts Receivable	1.28	1.87	-2.89	0.78	-1.07	0.04
Change in Accounts Payable	0.34	0.33	1.41	1.62	0.32	-0.19
Change in Unearned Revenue	-	-	33.51	-4.65	6.18	-
Change in Other Net Operating Assets	-8.21	-5.03	2.08	13.09	-0.7	0.77
Operating Cash Flow	-31.76	-38.97	4.04	-28.65	-9.31	-8.62
Capital Expenditures	-0.23	-0.73	-0.59	-0.76	-0.5	-0.76
Sale of Property, Plant & Equipment	0.09	-	-	-	-	-
Investment in Securities	-24.45	-16.91	9.93	-42.78	-	-0.03
Investing Cash Flow	-24.59	-17.64	9.35	-43.55	-0.5	-0.79
Long-Term Debt Issued	-	0.47	0.61	0.68	2.03	1.27
Total Debt Issued	0.48	-	-	-	-	-
Long-Term Debt Repaid	-	-1.04	-0.34	-0.34	-0.24	-0.1
Total Debt Repaid	-0.97	-	-	-	-	-
Net Debt Issued (Repaid)	-0.48	-0.57	0.27	0.34	1.79	1.18
Issuance of Common Stock	0.01	-	0.02	94.19	-	-
Financing Cash Flow	-0.47	-0.57	0.28	151.16	18.97	1.18
Foreign Exchange Rate Adjustments	-0.59	1.08	-4.21	-3.92	-0.68	-0.43
Net Cash Flow	-57.42	-56.1	9.46	75.05	8.48	-8.66
Free Cash Flow	-31.99	-39.7	3.46	-29.41	-9.81	-9.38
Free Cash Flow Margin	-255.18%	-586.53%	17.82%	-549.74%	-261.78%	-
Free Cash Flow Per Share	-1.19	-1.49	0.13	-1.49	-24.58	-20.95
Levered Free Cash Flow	-21.96	-24.82	-15.88	-20.99	-5.05	-
Unlevered Free Cash Flow	-21.96	-24.82	-15.88	-20.6	-4.83	-
Change in Net Working Capital	7.66	3.38	-1.59	-2.96	-3.82	-

Source: S&P Capital IQ. Standard template.